Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Acadia Pharmaceutica 12830 El Camino Real Suite 400 SAN DIEGO CA 92130 USA

www.acadia-pharm.com Employees: 654 P: 858-558-2871 F: 858-212-0513

Sector:

Medical

Description:

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. The company suffered a setback when the FDA issued a complete response letter to the supplemental new drug application for Nuplazid for treating dementia-related psychosis. Acadia resubmitted the supplemental new drug application to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis. Notably, several additional studies on Nuplazid n targeting different CNS indications, such as'dementia-related psychosis, schizophrenia inadequate response, schizophrenia negative symptoms and as an adjunctive treatment of major depressive disorder (MDD) are currently underway.

Key Statistics

Overview:

Market Capitalization, $K 3,774,013
Enterprise Value, $K 3,454,423
Shares Outstanding, K 167,362
Annual Sales, $ 957,800 K
Annual Net Income, $ 226,450 K
Last Quarter Sales, $ 244,320 K
Last Quarter Net Income, $ 18,990 K
EBIT, $ 88,360 K
EBITDA, $ 94,940 K
60-Month Beta 0.64
% of Insider Shareholders 26.50%
% of Institutional Shareholders 96.71%
Float, K 123,011
% Float 73.50%
Short Volume Ratio 0.76

Growth:

1-Year Return 25.18%
3-Year Return 56.38%
5-Year Return -48.11%
5-Year Revenue Growth 182.47%
5-Year Earnings Growth 141.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.11 on 05/07/25
Next Earnings Date 08/05/25 [--]
Earnings Per Share ttm 0.68
EPS Growth vs. Prev Qtr -35.29%
EPS Growth vs. Prev Year 10.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ACAD Ratios

Ratio
Price/Earnings ttm 32.37
Price/Earnings forward 44.54
Price/Earnings to Growth 4.74
Return-on-Equity % 17.46%
Return-on-Assets % 10.75%
Profit Margin % 23.64%
Debt/Equity 0.00
Price/Sales 3.85
Price/Cash Flow 31.23
Price/Book 4.81
Book Value/Share 4.57
Interest Coverage -1.75
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar